Colorectal Cancer – Pipeline Review, H2 2016
- Pages: 1645
- Published: December 2016
- Report Code: GMDHC8870IDB
Global Markets Direct’s, ‘Colorectal Cancer – Pipeline Review, H2 2016’, provides an overview of the Colorectal Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Colorectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape of Colorectal Cancer
The report reviews pipeline therapeutics for Colorectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Colorectal Cancer therapeutics and enlists all their major and minor projects
The report assesses Colorectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Colorectal Cancer
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Colorectal Cancer
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Colorectal Cancer pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
2cureX ApS
3-V Biosciences Inc
3M Drug Delivery Systems
3SBio Inc
4SC AG
AB Science SA
AbbVie Inc
AbGenomics International Inc
Accelerated Pharma Inc
Adamed Sp z oo
Aduro BioTech Inc
Advenchen Laboratories LLC
Alchemia Ltd
Allinky Biopharma
Amal Therapeutics SA
amcure GmbH
Amgen Inc
Antibe Therapeutics Inc
Apac Biotech Pvt Ltd
Apexigen Inc
Aphios Corp
Aposense Ltd
Arisaph Pharmaceuticals Inc
ARMO Biosciences Inc
ArQule Inc
Array BioPharma Inc
Asana BioSciences LLC
Aslan Pharmaceuticals Pte Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
ATLAB Pharma SAS
AVEO Pharmaceuticals Inc
B Cell Design SAS
Basilea Pharmaceutica Ltd
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
BeyondSpring Pharmaceuticals Inc
Biocon Ltd
Bionomics Ltd
Bionovis SA
Biotecnol Ltd
Biothera Pharmaceutical Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Company
Burzynski Research Institute Inc
Calithera Biosciences Inc
Cancer Prevention Pharmaceuticals Inc
Carna Biosciences Inc
Cascadian Therapeutics Inc
CBT Pharmaceuticals Inc
CCRP Therapeutics GmbH
Celgene Corp
Cellceutix Corp
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Celltrion Inc
Celyad SA
Chiome Bioscience Inc
Chipscreen Biosciences Ltd
ChoDang Pharm Co Ltd
Cipla Ltd
Cleave Biosciences Inc
Cleveland BioLabs Inc
COARE Biotechnology Inc
Coherus BioSciences Inc
Compugen Ltd
Cornerstone Pharmaceuticals Inc
Corvus Pharmaceuticals Inc
Critical Outcome Technologies Inc
CrystalGenomics Inc
Cytune Pharma SAS
Daiichi Sankyo Company Ltd
DanDrit Biotech A/S
Deciphera Pharmaceuticals LLC
Dicerna Pharmaceuticals Inc
Double Bond Pharmaceutical International AB
Dr. Reddy's Laboratories Ltd
EirGenix Inc
Eisai Co Ltd
Eli Lilly and Company
Endor Nanotechnologies SL
enGene Inc
EnGeneIC Ltd
Ensol Biosciences Inc
EntreChem SL
Enzo Biochem Inc
Etubics Corp
Exelixis Inc
F. Hoffmann-La Roche Ltd
Five Prime Therapeutics Inc
Formosa Laboratories Inc
Fusion Antibodies Ltd
Gene Techno Science Co Ltd
Genentech Inc
Genor BioPharma Co Ltd
Genoscience Pharma
Genzyme Corp
Gilead Sciences Inc
GlaxoSmithKline Plc
Glycotope GmbH
Golden Biotechnology Corp
Green Cross Corp
Hadasit Medical Research Services & Development Ltd
Handok Inc
Hanmi Pharmaceuticals Co Ltd
Heat Biologics Inc
Hemispherx Biopharma Inc
Hutchison MediPharma Ltd
iDD biotech SAS
Ideaya Biosciences Inc
Ignyta Inc
Immodulon Therapeutics Ltd
ImmuneXcite Inc
Immunomedics Inc
Immunovative Therapies Ltd
Incanthera Ltd
Incyte Corp
Innovent Biologics Inc
Inovio Pharmaceuticals Inc
Interprotein Corp
Intezyne Technologies Inc
Ionis Pharmaceuticals Inc
IPD Therapeutics BV
Isofol Medical AB
Jeil Pharmaceutical Co Ltd
JHL Biotech Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
KaloBios Pharmaceuticals Inc
Kancera AB
Karyopharm Therapeutics Inc
Kura Oncology Inc
Laboratorio ELEA SACIF y A
Lee's Pharmaceutical Holdings Ltd
Lion Biotechnologies Inc
LipoMedix Pharmaceutical Inc
Loxo Oncology, Inc.
Mabion SA
Mabtech Ltd
mAbxience SA
MacroGenics Inc
Marina Biotech Inc
MediaPharma srl
MedImmune LLC
Medinet Co Ltd
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Merus NV
Microlin Bio, Inc.
MolMed SpA
Mologen AG
Morphotek Inc
Multimmune GmbH
Mycenax Biotech Inc
Natco Pharma Ltd
NatureWise Biotech & Medicals Corp
Nektar Therapeutics
Neovacs SA
Nerviano Medical Sciences Srl
Nippon Kayaku Co Ltd
NormOxys Inc
Northwest Biotherapeutics Inc
Novartis AG
Novogen Ltd
Noxxon Pharma AG
NuCana BioMed Ltd
OBI Pharma Inc
Oncobiologics Inc
Oncolytics Biotech Inc
OncoMed Pharmaceuticals Inc
Onconova Therapeutics Inc
Ono Pharmaceutical Co Ltd
Oryx GmbH & Co KG
Otsuka Holdings Co Ltd
Oxford BioMedica Plc
Pfizer Inc
Pharma Mar SA
PharmAbcine Inc
Pivot Pharmaceuticals Inc
Pivotal BioSciences Inc
PlantForm Corp
PLx Pharma Inc
Precision Biologics Inc
Prima BioMed Ltd
Propanc Health Group Corp
Provectus Biopharmaceuticals Inc
PsiOxus Therapeutics Ltd
Puma Biotechnology Inc
R Pharm
RedHill Biopharma Ltd
Redx Pharma Plc
Regeneron Pharmaceuticals Inc
Rexahn Pharmaceuticals Inc
Rgenix Inc
Rhizen Pharmaceuticals SA
Richter Gedeon Nyrt
Samumed LLC
Sanofi
Selvita SA
Shanghai Henlius Biotech Co Ltd
Shire Plc
Sigma-Tau SpA
Sigmoid Pharma Ltd
Sillajen Biotherapeutics
Solvotrin Therapeutics Ltd
Sorrento Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
SuviCa Inc
Symphogen A/S
Synermore Biologics Co Ltd
Taiho Pharmaceutical Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
Takeda Pharmaceutical Company Ltd
Tara Immuno-Oncology Therapeutics LLC
Targovax ASA
Tarveda Therapeutics Inc
Theravectys SA
Tiltan Pharma Ltd
Tocagen Inc
TRACON Pharmaceuticals Inc
Transgene SA
TyrNovo Ltd
United BioPharma Inc
Vaccinex Inc
VasGene Therapeutics Inc
Vaximm AG
Verastem Inc
Vertex Pharmaceuticals Inc
Viralytics Ltd
Wilex AG
WntResearch AB
XBiotech Inc
XuanZhu Pharma Co Ltd
Zymeworks Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.